Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster

Combo Of PARP Inhibitor And J&J's Zytiga Delays Progression In All-Comers

The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.

A positive Phase III trial of Lynparza in prostate cancer patients regardless of genetic mutation could lead to a significant label expansion for AstraZeneca PLC's PARP inhibitor that would have a dramatic impact on sales growth.

High-level results from the PROpel Phase III trial have shown that Lynparza (olaparib) in combination with Johnson & Johnson’s...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category